Forthyron 200 microgram tablet
País: Irlanda
Língua: inglês
Origem: HPRA (Health Products Regulatory Authority)
Características técnicas
(SPC)
03-05-2024
No momento, alguns documentos para este produto não estão disponíveis, você pode enviar uma solicitação ao nosso serviço de atendimento ao cliente e iremos notificá-lo assim que conseguirmos obtê-los.
Enviar pedido.
Enviar pedido.
Ingredientes ativos:
levothyroxine sodium
Disponível em:
Eurovet Animal Health B.V.
Código ATC:
QH03AA01
Dosagem:
200 Microgram
Forma farmacêutica:
Tablets
Grupo terapêutico:
Canine
Área terapêutica:
Hormone
Status de autorização:
Authorised
Características técnicas
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Forthyron 200 microgram tablet.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
200µg levothyroxine sodium per tablet equivalent to 194µg levothyroxine
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Tablet.
White to off white round tablets, scored on one side.
Tablets divisible into 4 parts.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of hypothyroidism in dogs.
4.3 CONTRAINDICATIONS
Do not use in dogs suffering from uncorrected adrenal insufficiency.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
The diagnosis hypothyroidism should be confirmed with appropriate tests.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 29/10/2010_
_CRN 7006850_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
A sudden increase in demand for oxygen delivery to peripheral tissues, plus the chronotropic effects of levothyroxine
sodium, may place undue stress on a poorly functioning heart, causing decompensation and signs of congestive heart
failure. Hypothyroid dogs suffering from hypoadrenocorticism have a decreased ability to metabolise levothyroxine
sodium and therefore an increased risk of thyrotoxicosis. Dogs with concurrent hypoadrenocorticism and
hypothyroidism should be stabilised with glucocorticoid and mineralocorticoid treatment prior to treatment with
levothyroxine sodium to avoid precipitating a hypoadrenocortical crisis. After this, thyroid tests should be repeated,
then gradual introduction of levothyroxine therapy, starting with 25% of the normal dose, increasing by 25%
increments every fortnight
Leia o documento completo
